Profile data is unavailable for this security.
About the company
Magforce AG is a Germany-based company engaged in the provision of nanotechnology solutions for health sector. Its non-invasive technology uses magnetic nanoparticles to combat tumors, without harmful effect on the healthy tissues. The Company's range of treatment products includes NanoTherm Therapie for treating tumors locally; NanoTherm, a fluid containing ferrous oxide molecules that penetrate deeply into the tumor tissues and reacting to the presence of a magnetic field; NanoActivator, which are iron oxide nanoparticles for tumors in all areas of the body, and NanoPlan, a software platform that facilitates therapy planning and adjusts proper temperatures for the treatment and and the necessary magnetic field strength. As of December 31, 2011, Nanostart AG held a 49.6%-stake in the Company.
- Revenue in EUR (TTM)351.98k
- Net income in EUR-10.57m
- Incorporated2005
- Employees69.00
- LocationMagforce AGMax-Planck-Strasse 3BERLIN 12489GermanyDEU
- Phone+49 303083800
- Fax+49 3 030838099
- Websitehttps://www.magforce.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Neovacs SA | 12.97k | -11.50m | 48.03k | 21.00 | 0.0002 | 0.0002 | -- | 3.70 | 2.76 | 2.76 | 0.0016 | 3.30 | 0.0003 | -- | 0.244 | 682.63 | -25.83 | -73.52 | -27.87 | -121.84 | -34,333.00 | -70,804.85 | -88,645.88 | -97,761.64 | -- | -- | 0.0255 | -- | -24.31 | 7.87 | -92.71 | -- | 24.84 | -- |
| MagForce AG | 351.98k | -10.57m | 119.73k | 69.00 | -- | 0.0045 | -- | 0.3402 | -0.3531 | -0.3531 | 0.0118 | 0.8967 | 0.0055 | 3.47 | 0.8532 | 5,101.16 | -16.47 | -3.78 | -31.53 | -6.78 | -89.95 | 25.30 | -3,004.22 | -295.23 | 0.0321 | -1.97 | 0.2485 | -- | -43.33 | -5.77 | -171.71 | -- | -- | -- |
| Pharnext SA | 24.36k | -36.17m | 350.10k | 44.00 | -- | -- | -- | 14.37 | -5,000.11 | -5,000.11 | 0.001 | -113.45 | 0.0016 | -- | 0.0034 | -- | -236.98 | -102.39 | -- | -205.02 | -164.78 | -- | -148,496.30 | -3,820.04 | -- | -2.35 | -- | -- | 112.88 | -- | -41.98 | -- | -0.8111 | -- |
| Elanix Biotechnologies AG | 34.91k | -2.04m | 565.66k | 0.00 | -- | -- | -- | 16.20 | -0.2578 | -0.2578 | 0.0045 | -0.2489 | 0.0032 | 2.22 | 0.5512 | -- | -18.39 | -16.80 | -22.49 | -18.01 | -399.91 | -- | -5,835.32 | -3,875.84 | 0.2438 | -- | -- | -- | -72.76 | -- | -24.56 | -- | -- | -- |
| Q2M Managementberatung AG | -100.00bn | -100.00bn | 581.19k | 0.00 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | 46.38 | -- | -389.28 | -- | -- | -- |
